‘We’re not doing 30 bets a year’: Vijay Pande on betting small after running $4B at a16z
Vijay Pande — who left a16z's roughly $4 billion biotech practice last year to start the much smaller, AI-native VZVC — talks about why biology is finally shifting from a "discovery" science to an "engineering" one, why clinical trials are still brutally expensive, and why he thi
Vijay Pande's transition from leading a16z's $4 billion biotech practice to starting his own, smaller venture firm VZVC, is a significant move that warrants attention. By choosing to start small, Pande is signaling a shift in his approach to investing, opting for a more focused and agile strategy. This change in approach may be attributed to the evolving landscape of biotechnology, where Pande believes the field is shifting from a "discovery" science to an "engineering" one.
The biotechnology industry has long been characterized by high-risk and high-reward investments, with clinical trials being a major bottleneck due to their exorbitant costs. Pande's comments on the persistence of expensive clinical trials highlight the challenges that still need to be addressed in the industry. However, his enthusiasm for the potential of AI-native approaches to transform biotech suggests that he sees opportunities for innovation and disruption.
As the biotech industry continues to evolve, it will be interesting to watch how Pande's new firm, VZVC, navigates this landscape. With a focus on AI-native investing and a smaller, more agile approach, VZVC may be well-positioned to capitalize on emerging trends and technologies. The tech industry should keep an eye on Pande's progress and the developments in biotech, as advancements in this field have the potential to drive significant breakthroughs and innovations in healthcare and beyond.
Originally reported by techcrunch.com. TechNews adds analysis for technology readers.